SANUWAVE Health, Inc. (SNWV): Entry into a Material Definitive Agreement

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 28, 202 6, Sanuwave Health, Inc., a Nevada corporation (the “Company”), entered into Amendment No. 1 to Credit Agreement and Waiver (the “Amendment”) to the credit agreement (the “Credit Agreement”), dated as of Sep

Event · Debt financing
Instrument
Amendment No. 1 to Credit Agreement and Waiver
Lender
JPMorgan Chase Bank, N.A.
Amount
$5,000 amendment fee

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 28, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$SNWV
Neutral
medium confidence
Mentioned
$SNWV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SNWVNeutralLow
01

Why it matters

The amendment adjusts covenant terms and borrowing limits, which could modestly affect the company's financing flexibility and stock perception.

02

Market read

Primary disclosure of a credit agreement amendment for a micro‑cap biotech; limited trading relevance.

03

What to watch

The $5,000 amendment fee is negligible; focus should be on the reduced $250k borrowing caps.

Relevance 6/10Novelty 6/10Timing: same day filing

Background

The filing is a standard SEC Form 8‑K reporting a material definitive agreement amendment to the company's credit facility.

Company-level read

Ticker impact

$SNWVNeutralMedium confidence
Context

Sanuwave Health entered an amendment to its credit agreement, waiving a covenant default and lowering permitted indebtedness limits.

Expected impact

likely slight downside as market prices in tighter borrowing limits

Evidence & confidence

Waiver of default is positive, but lower permitted debt and tighter restrictions may constrain growth, leading to modest pressure on the stock.

Market effects

May signal tighter credit conditions for small-cap biotech lenders.

Limited to U.S. microcap market; no broader regional effect.

Minimal global impact.

Counterpoint

Investors could view the covenant waiver as a sign of underlying liquidity stress.

Key entities

  • Sanuwave Health, Inc.

    Nevada‑based biotech firm filing the amendment.

  • JPMorgan Chase Bank, N.A.

    Administrative agent for the credit agreement.

Related articles

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$SNWVMedAI 8/10

SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE (SNWV) reported Q2 2026 revenue of $9.7M, down 3% from $10.1M, driven by lower capital equipment sales. UltraMIST applicator revenue rose 13% to $7.3M, while UltraMIST system revenue fell 34% to $2.3M. The company posted a $0.7M net loss and withdrew FY2026 guidance amid proposed 2027 Medicare reimbursement cuts.

$SNWVMed

Sanuwave Announces Q2 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 20

$SNWVMedAI 8/10

What's Going On With SANUWAVE Health Stock On Friday? - SANUWAVE Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.